Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

3.9K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.9K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

4.1K
The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
4.1K
Abnormal Proliferation02:23

Abnormal Proliferation

4.7K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.7K
Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

2.8K
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
2.8K
TGF - β Signaling Pathway01:16

TGF - β Signaling Pathway

7.9K
The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors...
7.9K
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

8.3K
Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
8.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Current and Novel Biomarkers for Diagnosis and Subtyping of Primary Aldosteronism.

Hypertension (Dallas, Tex. : 1979)·2026
Same author

First worldwide multicenter validation of the POLARIS preclinical polarizer across biological models and imaging paradigms.

Research square·2026
Same author

Hyperpolarization of [1-<sup>13</sup>C]Ketoisocaproate-d<sub>2</sub> by Reversible Exchange with Parahydrogen Enables Profiling of Branched-Chain-Amino-Acid Metabolism in Cellulo and in Vivo.

Advanced science (Weinheim, Baden-Wurttemberg, Germany)·2026
Same author

IL-1β/CXCL12 signalling orchestrates adipocyte-pancreatic neuroendocrine tumor crosstalk.

Journal of translational medicine·2026
Same author

Prevalence of somatic SF3B1R625H mutation in lactotroph tumours from a multi-centric cohort: a digital PCR-based study.

European journal of endocrinology·2026
Same author

Pathology and Genetics in a Global Cohort of Parkinsonian Disorders.

JAMA neurology·2026

Related Experiment Video

Updated: Sep 30, 2025

Author Spotlight: Unveiling Transmembrane Protein Family-Related Markers in Gastric Cancer and Implications for Targeted Therapies
07:47

Author Spotlight: Unveiling Transmembrane Protein Family-Related Markers in Gastric Cancer and Implications for Targeted Therapies

Published on: September 15, 2023

1.7K

Angpt2/Tie2 autostimulatory loop controls tumorigenesis.

Ninelia Minaskan Karabid1,2, Tobias Wiedemann1,2, Sebastian Gulde1,2

  • 1Institute for Diabetes and Cancer, Helmholtz Zentrum München, Neuherberg, Germany.

EMBO Molecular Medicine
|March 10, 2022
PubMed
Summary

New research reveals the angiopoietin-2 (ANGPT2)/TIE2 pathway drives nonfunctioning pituitary neuroendocrine tumor (PitNET) growth. Targeting this axis offers a promising therapeutic strategy for these aggressive, relapsing tumors.

Keywords:
PitNETsangiopoietin 2anti-angiopoietin biologicalstumor-bound Tie2tumor/endothelial cell crosstalk

More Related Videos

Identification of Transcription Factor Regulators using Medium-Throughput Screening of Arrayed Libraries and a Dual-Luciferase-Based Reporter
11:32

Identification of Transcription Factor Regulators using Medium-Throughput Screening of Arrayed Libraries and a Dual-Luciferase-Based Reporter

Published on: March 27, 2020

7.0K
Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo
08:19

Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo

Published on: July 20, 2019

6.1K

Related Experiment Videos

Last Updated: Sep 30, 2025

Author Spotlight: Unveiling Transmembrane Protein Family-Related Markers in Gastric Cancer and Implications for Targeted Therapies
07:47

Author Spotlight: Unveiling Transmembrane Protein Family-Related Markers in Gastric Cancer and Implications for Targeted Therapies

Published on: September 15, 2023

1.7K
Identification of Transcription Factor Regulators using Medium-Throughput Screening of Arrayed Libraries and a Dual-Luciferase-Based Reporter
11:32

Identification of Transcription Factor Regulators using Medium-Throughput Screening of Arrayed Libraries and a Dual-Luciferase-Based Reporter

Published on: March 27, 2020

7.0K
Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo
08:19

Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo

Published on: July 20, 2019

6.1K

Area of Science:

  • Endocrinology
  • Oncology
  • Molecular Biology

Background:

  • Invasive nonfunctioning pituitary neuroendocrine tumors (NF-PitNETs) are challenging to treat, often relapsing and causing significant comorbidities.
  • Current therapies for NF-PitNETs are frequently ineffective, necessitating the identification of novel therapeutic targets.

Purpose of the Study:

  • To investigate the role of the angiopoietin-2 (ANGPT2)/TIE2 axis in the growth and progression of NF-PitNETs.
  • To evaluate the therapeutic potential of targeting the ANGPT2/TIE2 signaling pathway in NF-PitNETs.

Main Methods:

  • Utilized GH3 PitNET cell line, primary human NF-PitNET cells, zebrafish and mouse xenografts, and MENX rats (an autochthonous NF-PitNET model).
  • Assessed ANGPT2/TIE2 expression and function in tumor cells, including TIE2 receptor activity and downstream signaling.
  • Investigated the effects of TIE2 gene deletion and pharmacological inhibition of the ANGPT2/TIE2 axis on PitNET growth in vitro and in vivo.

Main Results:

  • PitNET cells express functional TIE2 receptors and secrete bioactive ANGPT2, promoting tumor cell growth via autocrine and paracrine mechanisms.
  • ANGPT2 stimulation of TIE2 in PitNET cells activates proliferation signaling pathways.
  • TIE2 gene deletion and pharmacological inhibition of the ANGPT2/TIE2 axis significantly reduced PitNET growth in various preclinical models.

Conclusions:

  • The ANGPT2/TIE2 axis is a critical driver of NF-PitNET progression and represents a viable therapeutic target.
  • Targeting the ANGPT2/TIE2 pathway may offer a new treatment strategy for NF-PitNETs and potentially other tumors utilizing this axis.
  • Tumor cells can hijack angiogenic signaling pathways, like ANGPT2/TIE2, for their own growth, expanding understanding of tumor microenvironment interactions.